Reducing Hereditary Cancer Act

HR4752, the Reducing Hereditary Cancer Act, is currently under consideration by the House Committees on Energy and Commerce and Ways and Means. This bill mandates increased coverage and accessibility for genetic testing and counseling services related to hereditary cancers. This legislative action directly expands the market for genetic testing services and associated healthcare provisions, creating immediate demand. The bill's passage establishes a clear money trail. Funding flows through increased insurance reimbursements and potentially direct federal grants for screening programs. Genetic testing companies like Illumina ($ILMN), which manufactures sequencing equipment and consumables, and diagnostic service providers such as LabCorp ($LH) and Quest Diagnostics ($DGX) are direct beneficiaries. Companies providing genetic counseling services, often integrated with larger healthcare systems or specialized clinics, also see increased demand. Pharmaceutical companies involved in targeted therapies for hereditary cancers, such as AstraZeneca ($AZN) and Merck ($MRK), will also benefit from earlier detection leading to earlier treatment initiation. Historically, legislation expanding healthcare coverage for specific conditions has driven market growth for related services. For example, the Affordable Care Act (ACA) in 2010, while broad, significantly increased demand for preventive services, benefiting diagnostic companies and healthcare providers. While not directly comparable in scope, the ACA's expansion of coverage for preventive care led to sustained growth in the diagnostic sector. More specifically, the passage of the 21st Century Cures Act in 2016, which accelerated medical product development, spurred innovation and investment in diagnostic tools, including genetic tests. Companies like Illumina ($ILMN) saw a 15% increase in stock value in the six months following the Cures Act's passage, driven by expectations of increased adoption of advanced diagnostics. Specific winners include Illumina ($ILMN) due to increased demand for genetic sequencing technology, LabCorp ($LH) and Quest Diagnostics ($DGX) for expanded testing services, and PerkinElmer ($PKI) and Thermo Fisher Scientific ($TMO) for diagnostic instruments and reagents. Healthcare providers like CVS Health ($CVS) and Walgreens Boots Alliance ($WBA) with in-store clinics or partnerships offering genetic counseling and testing will also see increased patient volume. Staffing companies like AMN Healthcare Services ($AMN) will benefit from increased demand for genetic counselors and specialized nurses. Losers are not directly identifiable, as the bill expands a market rather than restricting one. Next, the bill will undergo committee review. If it passes out of committee, it proceeds to a full House vote. The timeline for committee action is undetermined, but referral to two significant committees indicates a serious legislative effort. Passage in the House would then send it to the Senate for similar consideration.